Targeting noncanonical epitopes in anti-cancer immunotherapy

Title : Targeting noncanonical epitopes in anti-cancer immunotherapy

Abstract:

MHC class I complexes can present antigenic peptides that have a sequence produced by post-translational mechanisms such as peptide splicing. Some examples of tumour-associated spliced epitopes have been investigated for their immunogenicity in the context of cancer so far. We developed several pipelines to identify and predict these noncanonical epitopes, which are freely available. In addition, we tested the immunogenicity and the potential for therapeutical applications for those associated to various forms of cancer.

Biography:

Prof. Michele Mishto is Professor in Immunobiology at the King’s College London and Senior Group leader at the Francis Crick Institute in London (UK). PhD in Medical Biotechnology at University of Bologna (ITA) and a long post-doc and project leader experience at the Institute of Biochemistry at Universitätsmedizin Charite’ Berlin (GER). His research focus on antigen presentation and proteasomes.